TGF-β1、SMAD3、CDC25A、CDC25B在食管鳞状细胞癌中的表达及意义

THE EXPRESSION OF TGF-β1,SMAD3,CDC25A,CDC25B IN ESOPHAGEAL SQUAMOUS CELL CANCER

目的研究转化生长因子-β1（transforming growth factor-β1，TGF—β1）、SMAD3、细胞分裂周期25（cell division cycle25，CDC25）A、B在食管癌中的表达情况及其异常表达与食管癌发生、发展之间的关系。方法利用逆转录聚合酶链反应方法检测44例同个体食管癌、癌旁组织、食管正常黏膜组织中TGF-β1、SMAD3、CDC25A、CDC25B mRNA的表达，采用流式细胞术检测同组38例食管癌和20例食管正常黏膜组织中SMAD3、CDC25A、CDC25B蛋白的表达。结果CDC25A、CDC25B在食管正常黏膜组织、癌旁组织、食管癌中表达呈逐渐增高趋势，TGF-β1、SMAD3呈逐渐下降趋势。结论TGF-β1、SMAD3、CDC25A、CDC25B的异常表达可能是引起食管癌发生和发展的因素，食管癌变早期即已出现，可以作为早期诊断的指标。CDC25A、CDC25B、SMAD3、TGF-β1，mRNA的表达异常与食管上皮癌变密切相关，有望为靶点指导抗肿瘤的基因治疗。

Objective To detect the expression of cell division cycle 25A（CDC25A）, cell division cycle 25B（CDC25B）, SMAD3, transforming growth factor-β1 （TGF-β1） in esophageal carcinoma and the relationship between the abnormal expression of these factors and the development of esophageal carcinoma. Methods Detecting the expression of CDC25A, CDC25B, TGF-β1, SMAD3 mRNA in 44 sample of esophageal carcinoma, paired adjacent mucosa to esophageal carcinoma and normal esophageal mucosa at surgical margin of esophageal carcinoma tissues by reverse transcription polymerase chain reaction（RT-PCR）. Flow cytometry（FCM） was performed to study the protein of CDC25A,CDC25B, SMAD3 in 38 sample primarily esophageal carcinoma and normal 20 sample esophageal mucosa. Results The expression of CDC25A, CDC25B in esophageal carcinoma was higher than others, showing the ascensus tendency in normal esophageal mucosa, adjacent mucosa to esophageal carcinoma and esophageal carcinoma three groups. The expression of TGF-β1 ,SMAD3 in esophageal carcinoma was lower than others, showing decreasing tendency in three groups above. Conclusion The abnormal expression of CDC25A,CDC25B,SMAD3,TGF-β1 may be related to the development of esophageal carcinoma,these abnormality can be detected the index of early diagnosis of antineoplastic gene therapy. in earlier period of esophageal carcinoma, so it can be used as the index of early diagnosis of esophageal carcinoma. Use these factors as the target of antineoplastic gene therapy.